Wave Life Sciences, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
WVE Nasdaq 2830 wavelifesciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Wave Life Sciences, Inc.

WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path - Oct 21st, 2026 9:02 pm
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage - Oct 21st, 2026 10:30 am
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for - Oct 21st, 2026 7:00 am
Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026 - Oct 20th, 2026 6:30 am
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026 - Oct 19th, 2026 6:30 am
Wave Life Sciences (WVE) Stock Fair Value Moves Lower As Analysts Cut Growth Views - Oct 17th, 2026 4:11 am
GSK (LSE:GSK) Following Its ADS Filing And The Case For Undervaluation - Oct 14th, 2026 12:11 pm
Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut? - Oct 14th, 2026 10:43 am
Wave Life Sciences to Present at Chardan’s 10th Annual Healthcare Conference - Oct 13th, 2026 6:30 am
GSK (LSE:GSK) Deepens Its Drug Pipeline Through Two Research Partnerships - Oct 7th, 2026 8:13 pm
Lilly, Foghorn part ways; Wave’s FDA-approved plans - Oct 1st, 2026 10:04 am
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD - Oct 1st, 2026 5:30 am
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development - Sep 30th, 2026 5:30 am
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - Sep 28th, 2026 7:57 am
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity - Sep 23rd, 2026 5:30 am
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer - Sep 22nd, 2026 5:30 am
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference - Sep 3rd, 2026 2:05 pm
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover - Aug 13th, 2026 7:05 am
Did U.S. Redomiciliation and Mixed 1H 2026 Results Just Shift Wave Life Sciences' (WVE) Investment Narrative? - Aug 7th, 2026 2:13 pm